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The Ca2-binding protein calmodulin (CaM) has been shown
to bind directly to cytoplasmic domains of some G protein-cou-
pled receptors, including the dopamine D2 receptor. CaM binds
to the N-terminal portion of the long third intracellular loop of
the D2 receptor, within an Arg-rich epitope that is also involved
in the binding to Gi/o proteins and to the adenosine A2A recep-
tor, with the formation of A2A-D2 receptor heteromers. In the
present work, by using proteomics and bioluminescence reso-
nance energy transfer (BRET) techniques, we provide evidence
for the binding of CaM to the A2A receptor. By using BRET and
sequential resonance energy transfer techniques, evidence was
obtained for CaM-A2A-D2 receptor oligomerization. BRET
competition experiments indicated that, in the A2A-D2 receptor
heteromer, CaM binds preferentially to a proximal C terminus
epitope of the A2A receptor. Furthermore, Ca2 was found to
induce conformational changes in the CaM-A2A-D2 receptor
oligomer and to selectively modulate A2A and D2 receptor-me-
diated MAPK signaling in the A2A-D2 receptor heteromer.
These results may have implications for basal ganglia disorders,
since A2A-D2 receptor heteromers are being considered as a tar-
get for anti-parkinsonian agents.
G-protein-coupled receptors are able to form homo- and
hetero-oligomers with unique biochemical and functional
characteristics (1–7), and they are easily detected in vitro by
using biophysical techniques (8–10). Heteromers of adenosine
A2A anddopamineD2 receptorswere one of the firstG-protein-
coupled receptor heteromers to be described (11). A close phys-
ical interaction between both receptors was shown using co-
immunoprecipitation and co-localization assays (11) and
fluorescence and bioluminescence resonance energy transfer
(FRET2 or BRET) techniques (12–14). At the biochemical level,
two types of antagonistic A2A-D2 receptor interactions have
been discovered that may explain the A2A-D2 receptor interac-
tions described both at the neuronal and behavioral level (11,
15–18). First, bymeans of an allosteric interaction in the recep-
tor heteromer, stimulation of A2A receptor decreases the affin-
ity of D2 receptor for their agonists (12). Second, the stimula-
tion of the Gi/o-protein-coupled D2 receptor inhibits the cAMP
accumulation induced by the stimulation of the Gs/olf-protein-
coupledA2A receptor (11, 17, 18). In viewof thewell known role
of dopamine in Parkinson disease, schizophrenia, and drug
addiction, it has been suggested that the A2A-D2 receptor inter-
actions in the central nervous system may provide new thera-
peutic approaches to combat these disorders (16, 19).
An epitope-epitope electrostatic interaction between an
Arg-rich epitope of the N terminus of the third intracellular
loop (3IL) of the D2 receptor and an epitope containing a phos-
phorylated Ser localized in the distal part of the C terminus of
the A2A receptor is involved in A2A-D2 receptor heteromer
interface (14, 20, 21). The same Arg-rich epitope of the D2
receptor is able to interact with CaM (22–25). In the absence of
phosphorylated residues, adjacent aspartates or glutamates,
which are abundant in CaM, may also form non-covalent com-
plexes with Arg-rich epitopes (26). Therefore, CaM can poten-
tially convey a Ca2 signal to the D2 receptor through direct
binding to the 3IL of the D2 receptor (22). Mass spectrometry
data have shown that bovine CaM can form multiple non-co-
valent complexes with an Arg-rich peptide corresponding to
the N-terminal region of the 3IL of the D2 receptor (VLR-
RRRKRVN) (24) as well as a peptide from the proximal C ter-
minus of theA2A receptor (24). This epitope, whose sequence is
291RIREFRQTFR300 in the human A2A receptor, also contains
several Arg residues. Since the suspected interaction between
the A2A receptor and CaMwas awaiting confirmation by assays
using complete proteins, the present study was undertaken to
demonstrate the existence of interactions between the A2A
* This work was supported, in whole or in part, by the National Institutes of
Health, NIDA, Intramural Research Program (to S. F. and A. S. W.). This work
was also supported by Spanish Ministry of Education and Science Grants
SAF2008-00146 (to E. I. C.) and SAF2006-05481 (to R. F.) and Fundacio´ La
Marato´ de TV3 Grant 060110 (to E. I. C.). The Proteomics Laboratory at
CIMAbelongs to the network of the SpanishNational Institute of Proteom-
ics Facilities, ProteoRed.
1 Towhomcorrespondence should be addressed: CIMANeurociencias, Avda.
Pio XII 55, 31008 Pamplona, Spain. Tel.: 34-934021208; Fax: 34-934021559;
E-mail: rfranco@unav.es.
2 The abbreviations used are: FRET, fluorescence resonance energy transfer;
BRET, bioluminescence resonance energy transfer; CaM, calmodulin; SRET,
sequential resonance energy transfer; 3IL, third intracellular loop; MAPK,
mitogen-activatedprotein kinase; GFP, green fluorescent protein; YFP, yel-
low fluorescent protein; EYFP, enhanced yellow fluorescent protein; HBSS,
Hanks’ balanced salt solution; ERK, extracellular signal-regulated kinase.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 284, NO. 41, pp. 28058–28068, October 9, 2009
Printed in the U.S.A.
28058 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 41•OCTOBER 9, 2009
 by guest on M
arch 28, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
receptor and CaM both in a recombinant protein expression
cell system and in the brain. A proteomics approach was used
for the discovery of protein-protein interactions between the
A2A receptor and CaM in rat brain, whereas BRET in trans-
fected cells demonstrated a direct interaction between CaM
and this receptor. Furthermore, by using BRET and sequential
resonance energy transfer (SRET) techniques and analyzing
MAPK signaling in transfected cells, evidence was obtained for
CaM-A2A-D2 receptor oligomerization and a selective Ca2-
mediated modulation of A2A and D2 receptor function in the
A2A-D2 receptor heteromer.
EXPERIMENTAL PROCEDURES
Animals—Male Sprague-Dawley rats (250 g) were obtained
from Harlan (Barcelona, Spain). Procedures involving animals
were in accordance with the guidelines established by the nor-
mative of the EuropeanCouncil (86/609/EEC). The experimen-
tal design was approved by the Ethical Committee for Animal
Testing of the University of Navarra (060/07).
Membrane Protein Purification—Animals were killed by
decapitation, and the brains were rapidly removed. To obtain
P2 membrane proteins, the striatum was dissected out and
homogenized with a glass-Teflon homogenizer in ice-cold 0.32
M sucrose, 10 mM Hepes (pH 7,4), 2 mM EDTA, and complete
protease inhibitors (Roche Applied Science). After spinning at
1,000 g for 15 min, the supernatant was removed and centri-
fuged at 200,000  g for 15 min to yield the crude membrane
pellet (P2). The pellet was resuspended in homogenization
buffer and spun again at 200,000  g to yield washed crude
membrane pellet (P2).
Immunoprecipitation—The pellet containing membrane
proteins (P2) was solubilized in immunoprecipitation buffer
(phosphate-buffered saline (pH 7.4), complete protease inhibi-
tor mixture, and 1% Igepal Ca-630 (Sigma)) for 1 h at 4 °C.
Protein concentration was determined by the BCA method
(Pierce). A total amount of 0.5 mg of protein was used for
immunoprecipitation. Samples were pretreated with 30 l of
protein A/G-agarose beads (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) with gentle rocking for 1 h at 4 °C and centri-
fuged at 10,000  g to remove the beads. Membrane proteins
were incubated with 5 g of polyclonal anti A2A receptor
(Affinity Bioreagents, bioNova Científica, Madrid, Spain) or
with 5 g of normal rabbit IgG (Upstate, Charlottesville, VA)
for 90min, and then 30l of ProteinA/Gbeadswere added and
left for 16 h at 4 °C with gentle rocking. Immunoprecipitated
proteins were washed three times with immunoprecipitation
buffer.
Proteomic Analysis—Immunoprecipitated proteins were
analyzed in the Proteomic Laboratory of CIMA. Briefly, pro-
teins were eluted by incubation with 100 mM glycine-HCl (pH
2.5) for 10 min at room temperature with gentle rocking. The
samples were centrifuged at 10,000  g for 1 min, and the
supernatant content was precipitated with 25% trichloroacetic
acid for 20 min at 4 °C. After spinning at 10,000 g for 15 min,
the pellet waswashed twicewith precooled acetone, completely
dried in a SpeedVac, and resuspended in 30 l of 100 mM
ammonium bicarbonate. Proteins were reduced with 10 mM
dithiothreitol for 30min at 56 °C, alkylated with 55mM iodoac-
etamide for 20min in darkness, and finally digestedwith trypsin
1:50 (v/v) for 16 h at 37 °C. Peptide mass fingerprinting was
obtained from tryptic digests by liquid chromatography-elec-
trospray ionization-tandemmass spectrometry analysis (27). A
peak list was generated by ProteinLynx Global Server 2.1
(Waters, Milford, MA). A data base search was done with
ProteinLynx Global Server 2.1 (Waters) and Phenyx for raw
data and mzXML data, respectively. The data base used in this
study was SwissProt.
Cell Culture—HEK-293T cells were grown in Dulbecco’s
modified Eagle’s medium supplemented with 2 mM L-gluta-
mine, 100 units/ml penicillin/streptomycin, and 5% (v/v) heat-
inactivated fetal bovine serum (all supplements were from
Invitrogen). Cells weremaintained at 37 °C in an atmosphere of
5% CO2 and were passaged when they were 80–90% confluent
(i.e. approximately twice per week).
Mutant A2A Receptors, Fusion Proteins, and Expression
Vectors—The sequence R291IREFR296QTFR300 in the C-termi-
nal domain of the human A2A receptor was mutated to
A291IREFA296QTFA300 by site-directed mutagenesis (Celloge-
netics, Ijamsville, MD). The human cDNAs for A2A, mutant
A2A, which is denoted as A2ARAAA, D2, and A1 receptors,
cloned into pcDNA3.1, were amplified without their stop
codons using sense and antisense primers harboring unique
EcoRI and BamHI sites to clone A2A receptor, mutant A2A
receptor, or A1 receptor in Rluc vector and EcoRI and KpnI to
clone D2 receptor in Rluc or EYFP vectors. The amplified frag-
ments were subcloned to be in frame into restriction sites of
pcDNA3.1Rluc and pEYFP-N1 (enhanced yellow variant of
GFP; Clontech) vectors, resulting in the plasmids A2ARRluc,
A2ARAAARluc, A1RRluc, D2RRluc, and D2RYFP. The cDNA
encoding the human EYFP-CaM (CaMYFP) fusion protein was
kindly provided by Dr. Carles Enrich (Hospital Clinic de Barce-
lona, Spain). CaM was subsequently subcloned into the
pGFP2-C1 (BioSignal Packard, Montreal, Canada) using EcoRI
and BamHI, resulting in the GFP2-CaM plasmid. The cDNA
encoding the 5HT2BR-YFP fusion protein was kindly provided
by Dr. Irma Nardi (University of Pisa, Italy). Expression of con-
structs was tested by confocal microscopy (see “Results”), and
the receptor functionality was tested by second messengers,
ERK1/2 phosphorylation, and cAMP production, as described
previously (12, 14) (data not shown).
Transient Transfection and Protein Determination—HEK-
293T cells growing in 6-well dishes were transiently transfected
with the corresponding fusion protein cDNA by the polyethyl-
eneimine (Sigma) method. Cells were incubated (4 h) with the
corresponding cDNA together with polyethyleneimine (5
l/g cDNA of 10 M polyethyleneimine) and 150mMNaCl in
a serum-free medium. After 4 h, the medium was changed to a
fresh complete culture medium. Forty-eight hours after trans-
fection, cells were washed twice in quick succession in HBSS
with 10 mM glucose, detached by scraping, and resuspended in
the same buffer unless otherwise indicated. To control the cell
number, sample protein concentration was determined using a
Bradford assay kit (Bio-Rad), using bovine serum albumin as
the standard protein. Cell suspensions (20 g of protein) in
HBSS buffer containing 1.26 mM CaCl2 or, when indicated, in
Ca2-free HBSS buffer were distributed into 96-well micro-
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plates; black plates with a transparent bottom were used for
fluorescence determinations, whereas white plates were used
for BRET and SRET experiments.
BRET Assays—HEK-293T cells were transiently co-trans-
fected with the indicated amounts of plasmid cDNAs corre-
sponding to the indicated fusion proteins (see figure leg-
ends). To quantify fluorescence proteins, cells (20 g of
protein) were distributed in 96-well microplates (black
plates with a transparent bottom), and fluorescence was read
at 400 nm in a Fluo Star Optima Fluorimeter (BMG Labtech-
nologies, Offenburg, Germany) equipped with a high energy
xenon flash lamp, using a 10-nm bandwidth excitation filter.
Receptor fluorescence expression was determined as fluores-
cence of the sample minus the fluorescence of cells expressing
protein-Rluc alone. For BRETmeasurements, the equivalent of
20 g of cell protein was distributed in 96-well microplates
(Corning 3600, white plates; Sigma), and 5M coelenterazineH
(Molecular Probes, Inc., Eugene, OR) was added. After 1min of
adding coelenterazine H, the readings were collected using a
Mithras LB 940, which allows the integration of the signals
detected in the 485-nm short (440–500 nm) and the 530-nm
long (510–590 nm) wavelength filters. To quantify receptor-
Rluc expression, luminescence readings were performed after
10min of adding 5McoelenterazineH.The sameprotocolwas
used to determine BRET with membranes obtained from cells
(48 h post-transfection) disrupted using a Polytron homoge-
nizer (PTA 20 TS rotor, setting 3; Kinematica, Basel, Switzer-
land). Disruption was performed for three 5-s periods in 10
volumes of free Ca2 HBSS, pH 7.4, containing a proteinase
inhibitor mixture (Sigma). Cell debris were eliminated, mem-
branes were obtained by centrifugation at 105,000 g (40 min,
4 °C), and the pellet was resuspended and recentrifuged under
the same conditions. The net BRET is defined as (long wave-
length emission/short wavelength emission)  Cf, where Cf
corresponds to long wavelength emission/short wavelength
emission for the Rluc construct expressed alone in the same
experiment.
SRET Experiments—HEK-293T cells were transiently co-
transfected with the indicated amounts of plasmid cDNAs,
corresponding to the indicated fusion proteins (see the leg-
end for Fig. 6). Using aliquots of transfected cells (20 g of
protein), three different determinations were performed in
parallel. First, we performed quantification of protein-YFP
expression by determination of the fluorescence due to pro-
tein-YFP. Cells distributed into 96-well microplates (black
plates with a transparent bottom) were read in a Fluostar
Optima fluorimeter (BMG Labtechnologies, Offenburg, Ger-
many) equipped with a high energy xenon flash lamp, using an
excitation filter at 485 nm and 10-nm bandwidth emission fil-
ters corresponding to 510 nm (506–515 nm) (Ch1) and 530 nm
(527–536 nm) (Ch2). The contribution of the GFP2 and YFP
proteins alone to the two detection channels (spectral signa-
ture) (28) was measured in experiments with cells expressing
only one of these proteins and normalized to the sum of the
signal obtained in the two detection channels. The spectral sig-
natures of the different receptors fused to either GFP2 or YFP
did not vary significantly from the determined spectral signa-
tures of the fluorescent proteins alone. For protein-YFP expres-
sion quantification, linear unmixing was done taking into
account the spectral signature as described by Zimmermann
et al. (28, 29) to separate the two emission spectra; the sample
fluorescence is the fluorescence calculated as described minus
the fluorescence of cells expressing only protein-Rluc and pro-
tein-GFP2. Second, we performed quantification of protein-
Rluc expression by determination of the luminescence due to
protein-Rluc. Cells were distributed in 96-well microplates
(Corning 3600), and luminescencewas determined 10min after
the addition of 5 M coelenterazine H in a Mithras LB 940
multimode reader (Berthold Technologies, DLReady, Ger-
many). Third, we performed SRET2 measurements. Cells were
distributed in 96-well microplates (Corning 3600), and 5 M
DeepBlueC (Molecular Probes) was added. The SRET2 signal
was collected using a Mithras LB 940 reader with detection
filters for short wavelength (400 nm (370–450 nm)) and long
wavelength (530 nm (510–590nm)). By analogywithBRET, net
SRET is defined as (long wavelength emission/short wave-
length emission)  Cf, where Cf corresponds to long wave-
length emission/short wavelength emission for cells expressing
protein-Rluc, protein-GFP2, and the other protein partner not
fused to a fluorescence protein (similar values were obtained
measuringCf in cells expressing protein-Rluc only and protein-
GFP2). Linear unmixing was done for SRET2 quantification,
taking into account the spectral signature (28) to separate the
two fluorescence emission spectra.
Immunostaining—For immunocytochemistry, transiently
transfectedHEK-293T cells were fixed in 4%paraformaldehyde
for 15min andwashedwith phosphate-buffered saline contain-
ing 20 mM glycine (buffer A) to quench the aldehyde groups.
Then, after permeabilizationwith bufferA containing 0.2%Tri-
tonX-100 for 5min, cells were treatedwith phosphate-buffered
saline containing 1% bovine serum albumin. After 1 h at room
temperature, protein-Rluc was labeled with the primary mouse
monoclonal anti-Rluc antibody (1:100; Chemicon, Billerica,
MA) for 1 h, washed, and stained with the secondary antibody
Cy3 donkey anti-mouse (1:100; Jackson Immunoresearch Lab-
oratories, West Grove, PA). CaMYFP was detected by its fluo-
rescence properties. Samples were rinsed and observed in a
Leica SP2 confocal microscope (Leica Microsystems, Mann-
heim, Germany).
ERK Phosphorylation Assay—Cells were grown in 25-cm2
flasks to 80% confluence and cultured in serum-free medium
for 16 h before the addition of any agent. Cells resuspended in
HBSS buffer containing 1.26mMCaCl2were treated or notwith
1 M ionomycin for 3 min before the addition of the following
agonists: A2A receptor agonistCGS2168 (200nM), theD2 recep-
tor agonist quinpirole (1 M), or a mixture of both ligands for 5
min. Cells were rinsed with ice-cold phosphate-buffered saline
and lysed by the addition of 500 l of ice-cold lysis buffer (50
mMTris-HCl, pH 7.4, 50mMNaF, 150mMNaCl, 45mM-glyc-
erophosphate, 1%TritonX-100, 20Mphenyl-arsine oxide, 0.4
mM NaVO4, and protease inhibitor mixture). The cellular
debris was removed by centrifugation at 13,000 g for 5min at
4 °C, and the protein was quantified by the bicinchoninic acid
method using bovine serumalbumin dilutions as a standard. To
determine the level of ERK1/2 phosphorylation, equivalent
amounts of protein (10 g) were separated by electrophoresis
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on a denaturing 7.5% SDS-polyacrylamide gel and transferred
onto polyvinylidene difluoride membranes. The membranes
were then probed with a mouse anti-phospho-ERK1/2 anti-
body (1:2500; Sigma). In order to rule out the possibility that the
differences observed were due to the application of unequal
amounts of lysates, polyvinylidene difluoride blots were
stripped and probed with a rabbit anti-ERK1/2 antibody that
recognizes both phosphorylated and nonphosphorylated
ERK1/2 (1:40,000; Sigma). Bands were visualized by the addi-
tion of anti-mouse horseradish peroxidase-conjugated (Dako,
Glostrup, Denmark) or anti-rabbit horseradish peroxidase-
conjugated (Sigma) secondary antibodies, respectively, and
SuperSignal West Pico Chemiluminescent Substrate (Pierce).
Band densities were quantified with a LAS-3000 imaging sys-
tem (Fujifilm), and the level of phosphorylated ERK1/2 iso-
forms was normalized for differences in loading using the total
ERK protein band intensities. Quantitative analysis of detected
bands was performed by Image Gauge version 4.0 software.
One-way analysis of variance and Student’s t test for unpaired
samples were used for statistical comparisons.
RESULTS
Identification of an Interaction between CaM and the A2A
Receptor—According to the CaM target data base (available on
the World Wide Web), the sequence RIREFRQTFR, which is
present in the proximal part of theC terminus of theA2A recep-
tor, has a high probability to bind to CaM. In fact, we recently
demonstrated that a synthetic peptide with the same sequence
forms non-covalent complexes with bovine CaM (24). A pro-
teomics approach was then used to find in situ evidence of
direct interactions between the A2A receptor and CaM in the
brain. Samples from rat striatal membranes were immunopre-
cipitated using an antibody directed against a synthetic peptide
of the A2A receptor C terminus, SHGDMGLPDVELLSHELK,
which does not overlap with the putative CaM-binding motif.
Co-immunoprecipitates were digested with trypsin, and the
resulting peptides were analyzed by mass spectrometry, as
described under “Experimental Procedures.” Among other
peptides, two corresponding to the sequence of rat CaM
(P62161) were detected after co-immunoprecipitation with the
specific polyclonal antibody but not with rabbit IgG (Table 1).
The significance of the hits was confirmed by the low p values
for both the 13-mer and the 9-mer peptides, which collectively
covered 15% of the rat CaM sequence (Table 1). These results
suggest that CaM and the A2A receptor may interact, but the
existence of a third bridging protein cannot be ruled out. For
this purpose, BRET assays were performed in cells transfected
with the cDNAs for the A2ARRluc and CaMYFP fusion pro-
teins. The hyperbola obtained upon increasing the YFP/Rluc
ratio (Fig. 1A) indicates that a specific interaction betweenCaM
and the A2A receptor can occur in living cells. Similar experi-
ments were performed using D2RRluc and CaMYFP to confirm
that these two proteins may establish direct molecular inter-
actions (Fig. 1B). The specificity of the CaM and A2A recep-
tor or CaM and D2 receptor interactions in HEK cells was
confirmed by the nonspecific (linear) BRET signal obtained
when assaying A1RRluc and CaMYFP (Fig. 1). To demon-
strate that the A2A receptor sequence RIREFRQTFR acts as a
CaM binding domain, BRET competition experiments were
performed in cells transfected with the cDNAs for the
A2ARRluc and CaMYFP fusion proteins (amounts adjusted to
give values around the BRET50) and increasing amounts of
cDNA corresponding to the wild type A2AR or to the A2ARAAA
(RIREFRQTFR mutated to AIREFAQTFA). As expected, the
A2A receptor did decrease BRET values by competing with
A2ARRluc for its binding to CaMYFP, whereas A2ARAAA did
not (Fig. 2A). Accordingly, in cells expressing A2ARAAARluc
and CaMYFP, a linear and negligible BRET was detected in the
absence or in the presence of ionomycin (Fig. 2B).
FIGURE 1. Identification of CaM-A2A and CaM-D2 receptor oligomers by
BRET experiments. BRET saturation curves were performed using HEK-293
cells co-expressing A2ARRluc and CaMYFP (triangles) (A) or D2RRluc and
CaMYFP (inverted triangles) (B) or A1RRluc and CaMYFP (squares). Co-transfec-
tions were performed with increasing amounts of plasmid-YFP (0.1–1 g of
cDNA), whereas the plasmid-Rluc construct wasmaintained constant (0.6g
of cDNA for A2ARRluc, 1 g of cDNA for D2RRluc, and 0.7 g of cDNA for
A1RRluc). Both fluorescence and luminescence for each sample were meas-
ured before every experiment to confirm similar donor expressions (about
100,000 luminescent units)whilemonitoring the increase in acceptor expres-
sion. The relative amount of acceptor is given as the ratio between the fluo-
rescence of the acceptor (YFP) and the luciferase activity of the donor (Rluc).
BRET data are expressed as means  S.D. of 4–8 different experiments
grouped as a function of the amount of BRET acceptor.
TABLE 1
Peptides identical to the rat calmodulin sequence identified by
liquid chromatography-electrospray ionization-tandemmass
spectrometry
Sequence Position z dm/z z-Score p value
ADQLTEEQIAEFK 2–14 2 0.014 11.76 1.45E30
DTDSEEEIR 79–87 2 0.035 4.16 4.8E4
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CaM Interacts with A2A and D2 Receptors at the Plasma
Membrane—Immunolocalization of receptors and CaM were
performed in co-transfected HEK cells. When expressed in the
absence of receptors, CaM showed a cytosolic localization (Fig.
3). Co-expression of CaM and any of the two receptors did not
modify the localization of the receptor. On the other hand, a
significant membrane localization of CaM was only observed
when the proteinwas co-expressedwith eitherA2A orD2 recep-
tors (Fig. 3). The translocation ofCaM to the plasmamembrane
did not take place when co-expressed with the A1 receptor (Fig.
3), which is not able to establishmolecular interactionswith the
protein (see above). Treatment of cells with a Ca2-free buffer
and EDTA or treatment with ionomycin did not modify colo-
calization of CaM and A2A or D2 receptors in cell membranes
(Fig. 3).
Effect of Ca2 Levels on the Interaction betweenCaMandA2A
or D2 Receptors—BRET experiments were performed to give
some insight into the role of Ca2 in the interaction of CaM
with either A2A or D2 receptors. In cells co-expressing D2RRluc
and CaMYFP, resuspended in a medium containing 1.26 mM
CaCl2, ionomycin treatment led to significant decreases in
BRET measurements obtained after periods of incubation of 2,
5, and 10 min (Fig. 4B). In cells co-expressing A2ARRluc and
CaMYFP, ionomycin treatment also led to significant
decreases in BRET measurements at 2 and 5 min of preincu-
bation. In contrast, with a longer period of incubation (10
min), the BRET signal for A2ARRluc and CaMYFP increased
significantly above that found in untreated cells (Fig. 4A). On
the one hand, these data indicate that Ca2 is not needed for
CaM to be able to interact with A2A or D2 receptors. On the
other hand, the ionophore-induced increase in intracellular
Ca2 concentration does not disrupt the oligomerization of
CaM with the receptors but leads to conformational changes
in the CaM molecule and/or the receptors that alter the dis-
tance between Rluc (fused to the C terminus of the D2 or A2A
receptors) and YFP (fused to CaM). The observed effects are
not due to the Ca2 toxicity or changes in the membrane
structure, since they were also observed in a cell-free system
(Fig. 4D). Moreover, ionomycin did not induce significant
changes in BRET measurements in cells co-expressing
A1RRluc and CaMYFP (Fig. 4C).
Interactions of CaM with the A2A-D2 Receptor Heteromer—
By means of BRET competition experiments performed with
cells expressing A2RRluc and CaMYFP (with expression levels
adequate to give a suboptimal BRET value), the increase in D2
receptor expression (tested by Western blot experiments) did
not modify the BRET signal due to A2RRluc and CaMYFP (Fig.
5A). Analogously, increasing the expression of CaM did not
modify the BRET signal due to A2RRluc and D2RYFP (Fig. 5B).
As indicated in the Introduction, CaM seems to interact with
the Arg-rich epitope of the 3IL of the D2 receptor that is also
involved in A2A-D2 receptor heteromerization (see the Intro-
duction). In fact, competition assays demonstrated that
increasing amounts of A2A receptor led to significant reduction
in the BRET signal due to the interaction between theD2 recep-
tor and CaM (Fig. 5C). However, a differential effect was
obtained depending on the isoform of the D2 receptor (D2S or
D2L). On the one hand, the BRET signal between D2LRRluc and
CaMYFP increased with low quantities of A2A receptor but
decreased dose-dependently with higher quantities of A2A
receptor. On the other hand, using the pair D2SRRluc-
CaMYFP, a dose-dependent decrease in BRET was found.
These findings correlate with the potential ability of CaM and
A2A receptors to bind to any of the twoArg-rich epitopes of the
3IL of the D2L receptor (one of which is not present in the D2S
structure; see “Discussion”). The specificity of these effects was
demonstrated by the independence of the BRET signal with
increasing expression of the A1 receptor (Fig. 5C).
Oligomerization of CaM, A2A, and D2 Receptors—To test
the possible existence of CaM-A2A-D2 receptor oligomeriza-
tion, the recently described SRET technique was used (29).
FIGURE 2. Identification of the A2A receptor CaM binding site. A, BRET
competition experiments were performed with HEK-293 cells transfected
with A2ARRluc (0.6 g of cDNA), CaMYFP (0.6 g of cDNA), and increasing
amounts of cDNA corresponding to A2AR (white bars) or A2AR
AAA
(R291IREFR296QTFR300 mutated to A291IREFA296QTFA300; black bars). Both flu-
orescence and luminescence for each sample were checked to confirm simi-
lar donor and acceptor expression (about 100,000 luminescent units and
10,000 fluorescence units). A2AR and A2AR
AAA receptor expression was mon-
itoredbyWesternblot (not shown).B, BRET saturation curveswereperformed
with HEK-293 cells co-expressing A2AR
AAARluc (0.6 g of cDNA) and increas-
ing amounts of CaMYFP (0.1–1g of cDNA) and untreated (white symbols) or
treated (10 min; black symbols) with 1 M ionomycin in HBSS buffer contain-
ing 1.26mMCaCl2. Both fluorescence and luminescence of each sample were
checked to confirm similar donor expressions (about 100,000 luminescent
units) while monitoring the increase in acceptor expression. The relative
amount of acceptor is given as the ratio between the fluorescence of the
acceptor (YFP) and the luciferase activity of the donor (Rluc). BRET data are
expressed as means S.D. of 4–6 different experiments grouped as a func-
tion of the amount of BRET acceptor. Results are compared with the curve
obtained for A2ARRluc and CaMYFP (dotted line; see Fig. 1A).
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In SRET2, the oxidation of an Rluc
substrate triggers GFP2 acceptor
excitation by BRET2 and subse-
quent energy transfer to a YFP
FRET acceptor. SRET2 was at-
tempted using A2ARRluc, CaMGFP2,
D2RYFP, and DeepBlueC as Rluc
substrate. SRET2 would only occur
if the two acceptor/donor pairs,
A2ARRluc/CaMGFP2 and CaMGFP2/
D2RYFP, are well oriented at a dis-
tance of less than 10 nm. A SRET
saturation curve obtained by aug-
menting D2RYFP expression while
maintaining the same A2ARRluc/
CaMGFP2 ratio is shown in Fig. 6.
To obtain optimal results (see Ref.
29), cells were transfected with an
amount of cDNA (0.6 g) for
A2ARRluc giving readouts of about
100,000 luminescent units, an
amount of cDNA (0.4 g) for
CaMGFP2 giving about 6,000 fluo-
rescent units, and increasing amounts
of cDNA (0.5–6 g) for D2RYFP
(giving a range of 500–8,000 fluo-
rescence units). From the saturation
curve (Fig. 6), apparent SRETmax
(0.29  0.03) and apparent SRET50
(0.010  0.006) values were calcu-
lated. To prove whether SRET was
possible when substituting A2A
receptors byA1 receptors, cells were
transfected with 0.7g of cDNA for
FIGURE 3.Membrane colocalization of CaMwith A2A or D2 receptors. Co-transfected HEK-293 cells were washed and resuspended for 2.5 h in HBSS buffer
containing 1.26 mM CaCl2 (A–D and I–L) or in a Ca
2-free HBSS buffer containing 1 mM EDTA (E–H). A, E, and I, confocal microscopy images of HEK-293T cells
expressing (from left to right in each panel) CaMYFP (0.6 g of cDNA), A2ARRluc (1 g of cDNA), or D2RRluc (1 g of cDNA). B–D, F–H, and J–L, confocal
microscopy images of HEK-293T cells co-transfected with the above described amounts of cDNA for CaMYFP and A2ARRluc (B, F, and J), CaMYFP and D2RRluc
(C,G, and K), or CaMYFP and A1RRluc (1g of cDNA) (D,H, and L). Ionomycin-treated cells (10min prior to fixation) are shown in I–L. CaMwas identified by YFP
fluorescence (green images), and receptor-Rluc constructs were identified by immunocytochemistry (using a monoclonal anti-Rluc primary antibody and a
cyanine-3-conjugated secondary antibody). Colocalization (yellow) is shown in the right panels.
FIGURE 4. Effect of intracellular Ca2 on the interaction between CaM and A2A or D2 receptors
detected by BRET experiments. A–C, BRET saturation curves were performed using HEK-293 cells co-
expressing A2ARRluc and CaMYFP (A), D2RRluc and CaMYFP (B), or A1RRluc and CaMYFP as negative control
(C) (see the legend to Fig. 1). In all cases, cells were treated with HBSS buffer containing 1.26 mM CaCl2 and
1 M ionomycin at 10 (blue), 5 (green), or 2 (red) min before BRET determination. BRET saturation curves
were compared with the one obtained in the absence of ionomycin (dotted line; see Fig. 1). The relative
amount of acceptor is given as the ratio between the fluorescence of the acceptor (YFP) and the luciferase
activity of the donor (Rluc). BRET data are expressed as means  S.D. of 4–8 different experiments
grouped as a function of the amount of BRET acceptor. D, HEK-293 cells were transfected with 0.6 g of
cDNA for A2ARRluc (A2AR) or 1 g of cDNA for D2RRluc (D2R) and 1 g of cDNA of CaMYFP, andmembranes
were obtained 48 h after transfection. Membranes were resuspended in free Ca2 HBSS buffer, and 1.26
mM CaCl2 was added for the indicated times before BRET determination. BRET data are expressed as
means S.E. of five different experiments. Significant differences over ionomycin-non-treated cells were
calculated by one-way analysis of variance and Bonferroni test (*, p  0.05; **, p  0.01; ***, p  0.005).
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A1RRluc (100,000 luminescent units), 0.4 g of cDNA for
CaMGFP2 (6,000 fluorescent units), and 0.5–6 g of cDNA
for D2RYFP (500–9,000 fluorescence units). The possible
formation of a trimer in which the D2 receptor was substi-
tuted by the serotonin 5-HT2B receptor was tested using cells
transfected with 0.6 g of cDNA for A2ARRluc, 0.4 g of
cDNA for CaMGFP2, and 0.5–6 g of cDNA for the 5-HT2B
receptor (500–9,000 fluorescence units). Using these two
combinations of fusion proteins, a very low and non-saturating
(linear) SRET was observed, which indicates that oligomerization
FIGURE5.CaMinteractionwithA2A-D2 receptorheteromersdetectedbyBRETcompetitionexperiments.BRETcompetitionexperimentswereperformed
with HEK-293 cells expressing donor and acceptor constructs to give submaximal BRET values. A, cells were co-transfected with the cDNA corresponding to
A2ARRluc (0.6g) andCaMYFP (0.4g) and increasing amounts of D2R cDNAas competitor (0.3–2.5g), whose expressionwasmonitoredbyWestern blotting
(bottom) mBU,milli-BRET units. B, cells were cotransfectedwith the cDNA corresponding to A2ARRluc (0.6g) andD2LRYFP (1.5g) and increasing amounts of
cDNA of CaMGFP2 as competitor (0.2–1.5 g), whose expression was monitored by measuring the GFP2 fluorescence (1,000–20,000 fluorescence units), as
described under “Experimental Procedures.” To determine the YFP fluorescence in BRET experiments, the spectral signature was considered to control the
GFP2 contribution to the detection channel (28, 29). Cells were cotransfected with the cDNA corresponding to D2LRRluc (1 g; C) or D2SRRluc (0.8 g; D) and
CaMYFP (0.4g) and increasing amounts of cDNA of A2AR as competitor (black bars) or A1R as negative control (white bars), whose expression wasmonitored
by dot blotting (results not shown). At the top of each panel, a scheme depicts the expressed proteins in BRET competition assays.
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of CaM,A1, andD2 receptors or CaM,A2A, and 5-HT2B receptors
does not occur.
Effects of Intracellular Ca2 on CaM-A2A-D2 Receptor Oli-
gomerization—BRET was measured in the presence and in the
absence of ionomycin in cells co-transfected with A2ARRluc and
D2RYFP. The calcium ionophore led to qualitative changes in the
BRET curves (Fig. 7A) similar to those in the experiments with
cells co-expressingA2ARRlucandCaMYFP(seeFig.4A).Thus, the
BRETsignal forA2ARRluc andD2RYFPdecreasedat shorter times
of incubationwith ionomycin,whereas it increasedat longer times
(Fig. 7A). These results suggest that Ca2 binding toCaM induces
conformational changes in theA2A receptor such that thedistance
between the donor Rluc (fused to the C terminus of the A2A) and
theacceptorYFP ismodified.Takingall of the results intoaccount,
the most probable scenario is the existence of a CaM-A2A-D2
receptor oligomeric complex, Ca2 binding to CaM being unable
to disrupt A2A-D2 receptor heteromers. To further test this possi-
bility, SRET2 for A2ARRluc-CaMGFP2-D2RYFP was measured in
cells treatedwith ionomycin.As shown inFig. 6B, a positiveSRET2
was detected in the presence of ionomycin with an apparent
SRETmax of 0.24 0.08 and an apparent SRET50 of 0.051 0.003.
Therefore, calciumbinding toCaM led to a decrease in the appar-
entSRETmax andan increase in theapparentSRET50 values.CaM-
A2A-D2 receptor oligomers seem to be stable complexes that are
not disrupted by calcium binding to CaM.
Effects of Intracellular Ca2 on the Function of A2A-D2 Recep-
tor Heteromers—To test whether calcium binding to CaM-
A2A-D2 receptor oligomers modifies receptor functionality,
MAPK pathway signaling in cells expressing CaM and A2AR,
D2R, or both receptors was analyzed. ERK1/2 phosphorylation
was determined in cells treated with a 200 nM concentration of
the A2A receptor agonist CGS21680, and/or with 1 M D2
receptor agonist quinpirole in the presence and in the absence
of 1M ionomycin. As shown in Fig. 8A, activation of A2A or D2
receptors, in cells transfected with low amounts of cDNA for
CaM (0.3g) and expressing A2A orD2 receptors, induced sim-
ilar ERK1/2 phosphorylation in the absence or in the presence
of ionomycin. On the other hand, in cells transfected with 0.3
g of cDNA for CaM and expressing the two receptors, a dif-
ferent effect was obtained in the absence or in the presence of
ionomycin. In this case, ionomycin significantly reduced or
potentiated ERK1/2 phosphorylation induced by activation of
A2A or D2 receptors (Fig. 8B), respectively. The well known
antagonistic interaction between A2A and D2 receptors was
enhanced upon treatment with ionomycin. Results similar to
those in Fig. 8, A and B, were obtained if cells were expressing
higher amounts of CaM (1 g of cDNA; results not shown),
indicating that moderate amounts of exogenous CaM are
already able to modulate receptor operation. In contrast, the
effects of ionomycin were not observed in cells expressing only
endogenous CaM (Fig. 8C). Therefore, the effects of ionomycin
were dependent on the intracellular levels of CaM. Results sim-
ilar to those in Fig. 8, A and B, were also obtained using cells in
suspension (not adherent cells) (i.e. in the same conditions as
those used for BRET and SRET experiments) (results not
shown). Overall, the results suggest a correlation between
structural changes in the oligomer and the modulation of its
functionality exerted by Ca2 binding.
DISCUSSION
Ca2 plays an important role in the physiology of higher
order organisms and is involved in the regulation of many cel-
lular events. Various stimuli, such as membrane depolarization
or binding of ligands to plasma transmembrane receptors, trig-
ger Ca2 channel opening, which results in a significant influx
of Ca2 into the cytosol. Then Ca2-binding proteins act as
sensors andmediators of the initial Ca2 signal. CaM is a highly
conserved, soluble, intracellular 17-kDa Ca2-binding protein,
regarded as a major transducer of Ca2 signals in mammalian
cells (30). CaM has been shown to bind directly to cytoplasmic
domains of plasma membrane proteins, including G-protein-
coupled receptors, such as opioid , serotonin 5-HT1A, acetyl-
choline muscarinic, and dopamine D2 receptors (21, 31–33). In
the present work, we also provide clear evidence for the binding
of CaM to adenosine A2A receptors. It was demonstrated that
the sequence RIREFRQTFR, which is present in the proximal
part of the C terminus of the A2A receptor, is the CaM binding
domain in these receptors. Furthermore, we provide evidence
for CaM-A2A-D2 receptor oligomerization and for a specific
Ca2-dependent modulation of A2A-D2 receptor heteromer
function. Previous studies have shown that an Arg-rich domain
of the N-terminal portion of the 3IL of the D2 receptor is
involved in the binding to Gi/o proteins, CaM, and the A2A
FIGURE 6. SRET for CaM, A2A receptor andD2 receptor in living cells. SRET
saturation curveswereperformed inHEK-293 cells expressingA2AR-Rluc (0.75
g of cDNA), CaMGFP2 (0.6 g of cDNA), and increasing amounts of D2RYFP
(0.5–5 g of the cDNA). Net SRET was obtained by monitoring the YFP fluo-
rescence emission after coelenterazine H addition, with subtraction of the
value obtained with cells expressing the same amount of A2AR-Rluc and
CaMGFP2. Significant net SRET was detected for A2ARRluc-CaMGFP
2-D2RYFP
coupling, whereas negligible or linear net SRETwas obtained in cells express-
ing equivalent amounts (equivalent fluorescence and luminescence units) of
A2ARRluc, CaMGFP
2, and 5HT2BYFP or A1RRluc, CaMGFP
2, andD2RYFP, which
were used as negative controls. Values, expressed as net SRET, represent
means S.E. of five independent experiments performed in triplicate. At the
top, a scheme depicts the expressed proteins in SRET assays.
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receptor (14, 20, 22, 24, 34). The
binding of CaM to the D2 receptor
disrupts Gi/o coupling and, there-
fore, its ability to inhibit the activity
of adenylyl cyclase (22). We here
report competition of CaM and A2A
receptors for the same domain in
the D2 receptor. This competition
was particularly evident when the
short isoformof theD2 receptorwas
assayed. The two isoforms of the D2
receptor (short and long, D2S and
D2L, respectively) are generated by
alternative splicing (35). D2L, the
isoform used in most of the experi-
ments of the present study, contains
29 additional amino acid residues
within themiddle portion of the 3IL.
The Arg-rich epitope of the D2
receptor (VLRRRRKRVN) that is
able to interact with the A2A recep-
tor is common to both D2 receptor
isoforms and is localized in the
N-terminal portion of their long 3IL
(14, 20). However, there is an addi-
tional Arg-rich epitope in the 3IL of
D2L (VNRRRVEAA), which is not
present inD2S andwhich can poten-
tially interact with CaM or with
the A2A receptor (21). The VNR-
FIGURE 7. Effect of intracellular Ca2on themolecular interactions betweenCaM,A2A, andD2 receptors.
A, effect of Ca2 levels on theA2A-D2 receptor heteromerizationdetectedbyBRET. BRET saturation curveswere
performed with HEK-293 cells co-expressing A2ARRluc (0.6 g of cDNA) and increasing amounts of D2RYFP
(0.3–4g of cDNA). Cells in HBSS buffer containing 1.26mM CaCl2 were untreated (black) or treated with 1M
ionomycin for 2 (red), 5 (green) or 10 (blue) min before BRET determination. Both fluorescence and lumines-
cence for each sampleweremeasured to confirm similar donor expressions (about 100,000 luminescent units)
while monitoring the increase acceptor expression (1,000–15,000 fluorescent units). The relative amount of
acceptor is given as the ratio between the fluorescence of the acceptor (YFP) and the luciferase activity of the
donor (Rluc). BRET data are expressed as means S.D. of four different experiments grouped as a function of
the amount of BRET acceptor. mBU, milli-BRET units. B, effect of Ca2 levels on the CaM-A2A-D2 receptor
oligomerization detected by SRET. SRET saturation curves were performed in HEK-293 cells expressing
A2ARRluc, CaMGFP
2, and increasingamountsofD2RYFP, asdescribed in the legend toFig. 6. Cells inHBSSbuffer
containing1.26mMCaCl2were treatedwith1M ionomycin for 10minbeforeSRETdeterminationasdescribed
in the legend to Fig. 6, and the SRET saturation curve was compared with the one obtained in the absence of
ionomycin (dotted line; see Fig. 6).
FIGURE8.Effect of intracellular Ca2onA2A receptor-, D2 receptor-, andA2A-D2 receptor heteromer-mediated ERK1/2 phosphorylation.HEK-293
cells expressing A2A receptor (1.2 g of cDNA) or D2 receptor (1 g of cDNA) and CaM (0.3 g of cDNA) (A); A2A receptor (1.2 g of cDNA), D2R (1 g of
cDNA), and CaM (0.3 g of cDNA) (B); or A2A receptor (1.2 g of cDNA) and D2R (1 g of cDNA) (C) were placed in HBSS buffer containing 1.26 mM CaCl2
and treated 3 min with vehicle or with 1 M ionomycin before the addition of the A2A receptor agonist CGS21680 (200 nM; CGS), the D2 receptor agonist
quinpirole (1M), or both. A representativeWestern blot from ERK1/2 phosphorylation assays, which were performed as described under “Experimental
Procedures,” is shown. No significant differences in the basal levels were detected by the presence of CaM or CaM plus ionomycin. The immunoreactive
bands from 4–6 independent experiments were quantified, and values represent themean S.E. of percentage of increase of phosphorylation over the
basal levels (100%) found in ionomycin-untreated or -treated cells. Significant differences of agonist-treated versus basal (*) or agonist-treated in the
presence versus the absence of ionomycin (&) were calculated by one-way analysis of variance and Bonferroni test (* and &, p 0.05; ** and &&, p 0.01;
*** and &&&, p  0.005).
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RRVEAA peptide interacts in vitro with CaM and with a phos-
phorylated Ser-containing epitope of the C terminus of the A2A
receptor that is involved in A2A-D2 receptor heteromerization
(data not shown). In BRET competition experiments using
D2SRRluc-CaMYFP, the increase of A2A receptor expression
produced a significant decrease of the BRET signal. On the
other hand, when co-transfecting the A2A receptor, the BRET
signal betweenD2LRRluc and CaMYFP first increased, whereas
higher expression levels led to a reduced BRET signal. It is pos-
sible that, in the D2L receptor, CaM binds preferentially to the
VLRRRRKRVN epitope and that increasing quantities of trans-
fected A2A receptor induce, first, translocation of CaM to the
VNRRRVEAA epitope, thus leading to an enhancement of the
BRET signal. Upon further increase of receptor expression,
A2AR may also bind to the VNRRRVEAA epitope, with the
consequent displacement of CaM from the D2L receptor. The
results from BRET competition experiments demonstrating
that increasing expression of D2 receptor did not modify the
BRET signal due to A2RRluc and CaMYFP and that increasing
expression of CaM did not modify the BRET signal due to
A2RRluc and D2RYFP were also compatible with the possibility
of CaM-A2A-D2 receptor oligomerization with A2A receptors
able to bind simultaneously toCaMand to theD2 receptor. This
was demonstrated with the use of the recently introduced
sequential SRET techniques, which allow the demonstration of
direct interaction of three protein molecules (29).
The results not only indicated that CaM may interact with
A2A receptors in cells that express A2A-D2 receptor heteromers
but also that the conformation and function of A2A-D2 receptor
heteromers aremodulated byCa2. In fact ionomycin, an iono-
phore able to increase intracellular Ca2, did affect the energy
transfer between A2ARRluc and D2RYFP. Agonist-induced
conformational modifications in a receptor heteromer can be
demonstrated by using resonance energy transfer techniques
(36). In the case of the A2A-D2 receptor heteromer and by
means of the same techniques used in the present study, no
energy transfer variations were found after exposure to A2A or
D2 receptor agonists (12). Therefore, the ability of BRET tech-
niques to detect Ca2-triggered conformational changes
within the CaM-A2A receptor, CaM-D2 receptor, and CaM-
A2A-D2 receptor oligomers suggests that Ca2 exerts a strong
CaM-dependent control of the function of A2A and D2 recep-
tors and A2A-D2 receptor heteromers. Interestingly, Ca2
exerted a selective modulation of A2A-D2 receptor heteromer-
mediated activation of theMAPK pathway. On the other hand,
Ca2 binding to CaM did not individually modulate the recep-
tor-mediated signaling toward the MAPK pathway, and Ca2
significantly modified ERK1/2 phosphorylation induced by
activation of A2A or of D2 receptors in cells co-expressing the
two receptors. Furthermore, the previously described (18)
antagonistic interaction betweenA2A andD2 receptorswas reg-
ulated by ionomycin-mediated variation in the intracellular cal-
cium concentration.
The present study demonstrates the existence of oligo-
meric intermolecular interactions between CaM, A2A, and
D2 receptors. When not expressed together, A2A or D2
receptors may potentially bind CaM, but in cells expressing
the A2A-D2 receptor heteromer, CaM binds preferentially to
the A2A receptor. Furthermore, CaM transduces Ca2-de-
pendent changes of MAPK signaling in the CaM-A2A-D2
receptor oligomer. This work adds new information about
the function of A2A-D2 receptor heteromers, which are con-
sidered as a target for the development of anti-parkinsonian
agents (37).
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